Company intelligence / Profile preview
Celexor Bio
Oakland, California, United Statescelexorbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Celexor Bio's lead program, CLXR-901 (formerly IMG-018), is a depleting monoclonal antibody targeting ILT7 on plasmacytoid dendritic cells, licensed from Inmagene Biopharmaceuticals. The company is focused on advancing this candidate, which is preclinical, for severe autoimmune and inflammatory disorders[1][2][4][7].
- Therapeutic areas
- Immunology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Inmagene Biopharmaceuticals
Beyond the preview
Go deeper on Celexor Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celexor Bio.